432 related articles for article (PubMed ID: 11280753)
21. Mammalian DNA topoisomerase I activity and poisoning by camptothecin are inhibited by simian virus 40 large T antigen.
Pommier Y; Kohlhagen G; Wu C; Simmons DT
Biochemistry; 1998 Mar; 37(11):3818-23. PubMed ID: 9521701
[TBL] [Abstract][Full Text] [Related]
22. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
23. Structural insight of DNA topoisomerases I from camptothecin-producing plants revealed by molecular dynamics simulations.
Sirikantaramas S; Meeprasert A; Rungrotmongkol T; Fuji H; Hoshino T; Sudo H; Yamazaki M; Saito K
Phytochemistry; 2015 May; 113():50-6. PubMed ID: 25733498
[TBL] [Abstract][Full Text] [Related]
24. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity.
Beidler DR; Cheng YC
Mol Pharmacol; 1995 May; 47(5):907-14. PubMed ID: 7538195
[TBL] [Abstract][Full Text] [Related]
25. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.
Benedetti P; Fiorani P; Capuani L; Wang JC
Cancer Res; 1993 Sep; 53(18):4343-8. PubMed ID: 8395982
[TBL] [Abstract][Full Text] [Related]
26. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
Yang CJ; Horton JK; Cowan KH; Schneider E
Cancer Res; 1995 Sep; 55(18):4004-9. PubMed ID: 7664272
[TBL] [Abstract][Full Text] [Related]
27. Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping.
Reinhold WC; Kouros-Mehr H; Kohn KW; Maunakea AK; Lababidi S; Roschke A; Stover K; Alexander J; Pantazis P; Miller L; Liu E; Kirsch IR; Urasaki Y; Pommier Y; Weinstein JN
Cancer Res; 2003 Mar; 63(5):1000-11. PubMed ID: 12615715
[TBL] [Abstract][Full Text] [Related]
28. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture.
Tanizawa A; Pommier Y
Cancer Res; 1992 Apr; 52(7):1848-54. PubMed ID: 1312902
[TBL] [Abstract][Full Text] [Related]
29. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
[TBL] [Abstract][Full Text] [Related]
30. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
[TBL] [Abstract][Full Text] [Related]
32. Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells.
Mizutani K; Matsumoto K; Hasegawa N; Deguchi T; Nozawa Y
Exp Oncol; 2006 Sep; 28(3):209-15. PubMed ID: 17080014
[TBL] [Abstract][Full Text] [Related]
33. In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
Pondarré C; Strumberg D; Fujimori A; Torres-León R; Pommier Y
Nucleic Acids Res; 1997 Oct; 25(20):4111-6. PubMed ID: 9321666
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of resistance to topoisomerase I-targeting drugs.
Rasheed ZA; Rubin EH
Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
[TBL] [Abstract][Full Text] [Related]
35. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.
Goldwasser F; Bae I; Valenti M; Torres K; Pommier Y
Cancer Res; 1995 May; 55(10):2116-21. PubMed ID: 7743511
[TBL] [Abstract][Full Text] [Related]
36. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Jensen NF; Agama K; Roy A; Smith DH; Pfister TD; Rømer MU; Zhang HL; Doroshow JH; Knudsen BR; Stenvang J; Brünner N; Pommier Y
J Exp Clin Cancer Res; 2016 Mar; 35():56. PubMed ID: 27029323
[TBL] [Abstract][Full Text] [Related]
37. DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
Ng CE; Cybulski SE; Bussey AM; Aubin RA; Raaphorst GP
Anticancer Res; 1998; 18(4C):3119-26. PubMed ID: 9713520
[TBL] [Abstract][Full Text] [Related]
38. Enhanced CPT sensitivity of yeast cells and selective relaxation of Ga14 motif-containing DNA by novel Gal4-topoisomerase I fusion proteins.
Alessandri M; Beretta GL; Ferretti E; Mancia A; Khobta A; Capranico G
J Mol Biol; 2004 Mar; 337(2):295-305. PubMed ID: 15003448
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of camptothecin resistance by human topoisomerase I mutations.
Chrencik JE; Staker BL; Burgin AB; Pourquier P; Pommier Y; Stewart L; Redinbo MR
J Mol Biol; 2004 Jun; 339(4):773-84. PubMed ID: 15165849
[TBL] [Abstract][Full Text] [Related]
40. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
Hentze H; Latta M; Künstle G; Dhakshinamoorthy S; Ng PY; Porter AG; Wendel A
Hepatology; 2004 May; 39(5):1311-20. PubMed ID: 15122760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
